SUBSCRIBE
SUBSCRIBE
News   Business

AstraZeneca PLC (JOBS) Drug Development Head to Retire

November 4, 2008 | 
1 min read
LONDON, Nov 4 (Reuters) - AstraZeneca Plc's head of drug development, John Patterson, is to retire from the board of the Anglo-Swedish company next March, marking a key changeover at the top of the group.
People Europe
AstraZeneca
MORE ON THIS TOPIC
New Opportunity, Businessman Walks Up Stairs Finds Exit Big Door
FDA
FDA’s cell and gene therapy head steps down after 1 year
June 30, 2026
 · 
2 min read
 · 
Michael Gibney
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
China
Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard
June 30, 2026
 · 
1 min read
 · 
Annalee Armstrong
Solution Concept with Handshake on Chalkboard Background
Mergers & acquisitions
Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance
June 29, 2026
 · 
2 min read
 · 
Annalee Armstrong
Businessmen look at the city from the outskirts.
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac